ARS-1

Phase 2Small molecule

AARS Pharmaceuticals, Inc.

ARS-1 is one of 108 small molecule programs targeting Respiratory tract infection. It is currently in Phase 2.

Indications

Total Trials

Active Trials

107

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory Tract InfectionActive, not recruiting

UrticariaActive, not recruiting

AsthmaActive, not recruiting

Respiratory Tract InfectionPhase 1

Active, not recruiting

UrticariaPhase 2

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Cinqair

Teva

Preclinical

13 2

Spiriva

Boehringer Ingelheim

Preclinical

8 3

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 4

ARS-1

AARS Pharmaceuticals, Inc.

Phase 2

1 5

Atrovent

Boehringer Ingelheim

Preclinical

5 6

Formoterol Fumarate

AstraZeneca

Preclinical

8 7

Symbicort

AstraZeneca

Preclinical

6 8

Atrovent

Boehringer Ingelheim

Preclinical

2 9

Aciphex

Akero Therapeutics

Preclinical

2 10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Asthma1 trial

Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma

Completed·AARS Pharmaceuticals, Inc.·Phase 2·NCT05363670·18 enrolled

Respiratory tract infection1 trial

Pharmacokinetics of Adrenaline After Administration of ARS -1 in Subjects With Upper Respiratory Tract Infection

Completed·AARS Pharmaceuticals, Inc.·Phase 1·NCT04930900·15 enrolled

Urticaria1 trial

Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares

Completed·AARS Pharmaceuticals, Inc.·Phase 2·NCT05496465·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ARS-1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ARS-1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ARS-1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ARS Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AARS Pharmaceuticals, Inc.

ARS-1

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Asthma1 trial

Respiratory tract infection1 trial

Urticaria1 trial

References

Drug Info

Quick Facts

Related News